TABLE 1.
Baseline demographic and clinical characteristics of the final population
| Total (n = 148) |
SARS-CoV–2 pre-immunized (n = 31) |
SARS-CoV–2 naïve (n = 117) |
p-value | |
|---|---|---|---|---|
| Age (year) | 57.62 ± 14.32 | 52.42 ± 14.81 | 59.00 ± 52.42 | .022 |
| Sex (%female) | 29.1% | 28.2% | 32.3% | .661 |
| Diabetes (%yes) | 21.6% | 12.9% | 23.9% | .226 |
| BMI | 25.60 ± 4.23 | 25.48 ± 3.61 | 25.64 ± 4.39 | .857 |
| Ethnicity (%) | .058 | |||
| Caucasic | 90.5% | 80.6% | 93.2% | |
| Hispanic | 7.4% | 16.1% | 5.1% | |
| African | 2.0% | 3.2% | 1.7% | |
| Blood type (%)a | .964 | |||
| A | 49.3% | 51.6% | 48.7% | |
| B | 2.7% | 3.2% | 2.6% | |
| O | 43.9% | 45.2% | 43.6% | |
| AB | 1.4% | - | 1.7% | |
| Type of donor (%) | .257 | |||
| Living | 32.4% | 25.8% | 34.2% | |
| DBD | 41.2% | 48.4% | 39.3% | |
| DCD II | 6.8% | 12.9% | 5.1% | |
| DCD III | 19.6% | 12.9% | 21.4% | |
| Type of transplantation | .017 | |||
| Kidney | 89.9% | 77.4% | 93.2% | |
| Kidney-pancreas | 10.1% | 22.6% | 6.8% | |
| Time from transplant (years) | 1.65 [0.79–4.94] | 1.83 [1.04–7.46] | 1.62 [0.71–4.49] | .532 |
| Transplant <1 year (%) | 27.7% | 22.6% | 29.1% | .652 |
| Dialysis vintage (months) | 17 [4–37.5] | 13 [0.75–40.5] | 17 [5–38] | .685 |
| Previously transplanted (yes) | 23.0% | 19.4% | 23.9% | .810 |
| Any rejection (%yes) | 20.3% | 29.0% | 17.9% | .209 |
| Baseline cPRA I+II (%) | 0 [0–24] | 0 [0–7] | 0 [0–34] | .752 |
| eGFR CKD-EPI (ml/min) | 49.07 ± 20.06 | 52.48 ± 22.56 | 48.16 ± 19.34 | .288 |
| Leukocytes (/mm3) | 6263 ± 2038 | 6261 ± 1979 | 6263 ± 2062 | .995 |
| Hb (g/dl) | 13.31 ± 1.79 | 13.10 ± 1.78 | 13.37 ± 1.80 | .476 |
| Lymphocytes (/mm3) | 1400 ± 745 | 1371 ± 767 | 1408 ± 742 | .809 |
| Lymphopenia (<1000/mm3) (%yes) | 29.1% | 32.3% | 28.2% | .661 |
| Treated during the last year with (%yes) | ||||
| Antithymocyte globulins (ATG) | 11.5% | 6.5% | 12.8% | .527 |
| Rituximab | 2.0% | — | 2.6% | 1 |
a
Missing value in four cases.